Forum Day - 7th October


LSX World Congress USA forum day includes an investor-only forum providing a unique and powerful peer-to-peer discussion forum between the sector’s venture capital, PE and institutional executives.

There are also 3x CEO Forums for private early stage, private growth stage and publicly-listed company executives to uncover KSFs relating to their company stage.

09:00


LSX 1-2-1 Partnering 200x

1-2-1 partnering will take place in a dedicated room with private meeting tables and 30min allocated slots. 3 hours of enabled partnering outside of the informal networking during breaks will be scheduled.

12:00


Networking Lunch

13:00


LSX Investor Forum 200x

A unique, powerful and valuable space for the candid sharing of experience between the
sector’s venture capital and PE and executives. A pre-registration only, exclusive hollow
square forum where participants explore ideas and strategies, new thinking about the current investment landscape and how they can best navigate the year ahead, profitably and with success.

- A State of the Market presentation with views on M&A and Capital Markets
- 3-4 x interactive peer review case studies of recent investments, transactions or deals
- 2 x 45-minute focused discussion on appropriate funding, financing and strategic challenges
- Discussion on industry convergence, regulatory drivers, emerging sector opportunities and market volatilities

OR


LSX Early Stage CEO Forum 200xhosted by  Wilson Sonsini

A unique, powerful and valuable space for the candid sharing of experience between 30 of the sector’s pre-series A life science executives. A pre-registration only, exclusive hollow square forum where all participants are active discussants.

- Scene setting presentation with views on company growth and investment trends
- Case study: non-dilutive funding to advance R&D
Jeff Behrens, President & CEO, Siamab Therapeutics
- Case study: anatomy of a first round financing
Senior Executive from Wilson Sonsini Goodrich & Rosati + Biotech CEO to be confirmed
- Case study: international Investment and Company Building: Oncologie A + B with Asian investment partners
Laura Benjamin, Founder & CEO, Oncologie
- Case study: overcoming challenges in securing a substantial series A
Jake Becraft, Co-Founder & CEO, Strand Therapeutics
- Case study: early-stage partnerships to launch and grow your business
- Approx. 30mins of hollow square discussion around each of the above topics
- Plus 1hr of general macro challenge discussion not restricted to valuation, alternative growth strategies, asset commercial strategies and research partnerships

OR


LSX Growth Stage CEO Forum 200xco-hosted by IQVIA 300x-1   Morrison & Foerster 300x

A unique, powerful and valuable space for the candid sharing of experience between 30 of the sector’s post-series A life science executives. A pre-registration only, exclusive hollow square forum where all participants are active discussants.

- Scene setting presentations with views on transactional and clinical trends
- Case study: challenges in securing later stage investment
Dan Grau, CEO, Sojournix
- Case study: considerations for a commercialization model: how to optimize value to patients and stakeholders
Senior Executive from IQVIA + Biotech CEO to be confirmed
- Case study: taking your products through the clinic / clinical / R&D strategies
Adam Rosenberg, CEO, Rodin Therapeutics
- Case study: finding new directions for success after clinical failures
Neal Farber, CEO, NeuroHealing Pharmaceuticals  
- Case study: M&A as a strategic multiplier
Satish Sanan, Chairman and CEO, Inspirata, Inc.
- Case study: preparing commercial go-to-market, strategies and activities
John Glasspool, CEO, Anthos Therapeutics
- Approx. 30mins of hollow square discussion around each of the above topics
- Plus 1hr of general macro challenge discussion not restricted to valuations and dilutions, research partnerships, market access, pricing and exit dynamics

OR


LSX Public CEO Forum 200x

A unique, powerful and valuable space for the candid sharing of experience between 30 of the sector’s mid-cap publicly-listed executives. A pre-registration only, exclusive hollow square forum where all participants are active discussants

- Scene setting presentation with views on M&A and capital markets
- Case study: challenges in securing secondary placements and follow-on equity
Aoife Brennan, CEO, Synlogic Therapeutics (invited)
- Case study: securing debt financing to finance your business
Frederic Chereau, CEO, LogicBio (invited)
- Case study: late-stage partnerships and clinical / R&D strategies to commercialize and scale your business
Martin Driscoll, President & CEO, Springbank Pharmaceuticals 
- Case study: internationalization as a strategy to maximise the global potential of clinical pipelines
Johnson Lau, CEO, Athenex (invited)
- Case study: M&A as a strategic multiplier
Chaim Indig, CEO, Phreesia (invited)
- Approx. 30mins of hollow square discussion around each of the above topics
- Plus 1hr of general macro challenge discussion not restricted to market access and pricing and late stage partnerships

17:30


Networking Drinks & Dinners

DOWNLOAD THE BROCHURE